SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 643.39-0.6%10:23 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: CuttingEdge Bio who wrote (3113)10/17/2020 10:11:22 AM
From: Biotechwantabe  Read Replies (1) of 3557
 
Us cases
>50k/dy
1.5m/month

Production estimated
Regeneron 300k/m
Roche 1m

prophylaxis
Not enough supply to make a dent. To expensive to produce. Leave to vaccines except special small outbreaks- old age home....

Hospitalized
Still waiting for data. But if it works the probably be used to save lives.

Out of hospital
If distributed to all would consume full supply
If distributed to seronegative (old and comorbidity 20%) Then you might have enough supply.

Anyway, other companies will need to deliver vaccines and antibodies to make up for supply shortage.

Just not sure why government hasn’t stepped up to fund project to increase supply 10X. Just in case the other companies fail.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext